STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design, and look forward to STAMPEDE2 and their hopes for the future of prostate cancer research. - Further information is available on the STAMPEDE study page at www.mrcctu.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly/3OQWhV8 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future

9

8/23/2023

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. Part 1 covers the landscape of prostate cancer treatment before STAMPEDE, as well how the trial was designed, featuring two researchers who lead the methodological and clinical sides of the trial: Max Parmar, Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and UCL's Institute of Clinical Trials and Methodology, and Nick James, Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research.

2

8/9/2023

Episode 4 of #MadeAtUCL is all about maps! We're bringing you the glamour of prostate imaging, decoding a document of hidden histories from Northern Ireland and learning how maps can protect forests around the world. - Prof Mark Emberton on The Tumour Hunters: precision targeting for prostate cancer - Prof Tim Weyrich on the Great Parchment Book rising from the ashes - Prof Jerome Lewis on Citizen Science that helps conserve wildlife https://www.ucl.ac.uk/made-at-ucl/podcasts

226

3/19/2020

Professor Caroline Moore Head of Urology, UCL Honorary Consultant Urologist, UCLH Trust Rethinking Cancer | UCL Cancer Domain Symposium Monday 13 May 2019 Cancer detection: the earlier the better? Cancer remains one of the major causes of morbidity and premature death worldwide; one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime. UCL has a proud track record in addressing the societal, technical, and health challenges of cancer and in exploring its underling biology. This symposium, invited our broad community to assemble for the first time at scale to consider challenges and opportunities in cancer research, prevention and treatment, from biological, clinical, technical, economic and societal perspectives.

612

6/4/2019